Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)
Dipeptidyl peptidase 4 (DPP4) has been proposed as a coreceptor for SARS-CoV-2 cellular entry. Considering that type 2 diabetes mellitus (T2DM) has been identified as the most important risk factor for SARS-CoV-2, and that gliptins (DPP4 inhibitors) are a prescribed diabetic treatment, this study ai...
Saved in:
Published in | Life sciences (1973) Vol. 336; p. 122292 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.01.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!